234 related articles for article (PubMed ID: 22783570)
21. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
22. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
23. Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
Nelson KK; Gattuso P; Xu X; Prinz RA
Surgery; 2010 Oct; 148(4):654-60; discussion 660. PubMed ID: 20797751
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
[TBL] [Abstract][Full Text] [Related]
25. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
[TBL] [Abstract][Full Text] [Related]
27. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
Scognamiglio T; Hyjek E; Kao J; Chen YT
Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
32. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid.
Manivannan P; Siddaraju N; Jatiya L; Verma SK
Indian J Biochem Biophys; 2012 Oct; 49(5):392-4. PubMed ID: 23259327
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
34. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
35. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
39. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors.
Jacques C; Guillotin D; Fontaine JF; Franc B; Mirebeau-Prunier D; Fleury A; Malthiery Y; Savagner F
J Clin Endocrinol Metab; 2013 May; 98(5):E981-9. PubMed ID: 23569218
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
